SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
A comprehensive website for sharing fundamental information about biochemical pathways and genomes with researchers around the world.
SRI’s Brown Laboratory is utilizing cell-targeting peptides to deliver active therapeutic cargo to specific cells in vivo.
Novel molecular targets of several cytokines are being evaluated by SRI scientists, with the goal of designing a small-molecule drug to block responses involved in many of these inflammatory diseases.
EcoCyc is SRI's bioinformatics database that describes the genome and the biochemical machinery of Escherichia coli.
SRI is seeking new treatments for tuberculosis, a global health crisis.
SRI’s Brown Laboratory is using selected peptides as “fishing hooks” to identify novel cell surface features.
SRI is investigating novel methods and treatments to improve cognitive deficits caused by diseases such as Alzheimer’s and depression.
Partnering to Advance Therapy for Radiation Exposure
Through a broad range of services for the National Institutes of Health, SRI is accelerating preclinical development of potential therapies for diseases that affect millions of people.
SRI is developing a method to enable rapid, large-scale response to a bioterrorism threat or an infectious disease epidemic.
SRI's Brown Laboratory is taking multiple approaches to develop effective anti-cancer immunotherapies.
Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.